ATLANTA, April 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY - News), a biomaterials, medical device and tissue processing company, today announced that its BioDisc(TM) Nucleus Pulposus Replacement will be featured at two separate medical conferences in Berlin, Germany, this week. BioDisc, now undergoing clinical evaluation, is a fast-setting protein hydrogel designed to fill the void created during the removal, or discectomy, of nucleus material after a lumbar spinal disc herniation.
